Skip to content

Krystal Biotech

US · KRYS #1515 by market cap Listed 2017
308.89 -6.93 -2.19%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    Citi Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $386
    Market Newswire · 2026/8/4
  • Rating change
    H.C. Wainwright Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $361
    Market Newswire · 2026/6/16
  • A Quick Look at Today's Ratings for Krystal Biotech(KRYS.US), With a Forecast Between $361 to $412
    Market Newswire · 2026/11/3
  • Rating change
    BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Cuts Target Price to $392
    Market Newswire · 2026/8/4
  • Rating change
    BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $400
    Market Newswire · 2026/9/21
  • Rating change
    BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $396
    Market Newswire · 2026/7/14
  • Rating change
    Jefferies Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $474
    Market Newswire · 2026/7/13
  • Rating change
    RBC Capital Initiates Krystal Biotech(KRYS.US) With Buy Rating, Announces Target Price $400
    Market Newswire · 2026/8/15
  • Rating change
    H.C. Wainwright Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $361
    Market Newswire · 2026/10/16
  • Rating change
    Citi Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $416
    Market Newswire · 2026/10/16
  • Rating change
    Citi Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $416
    Market Newswire · 2026/10/16
  • TD Cowen Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $403
    Market Newswire · 2026/10/21
  • Rating change
    Goldman Sachs Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $441
    Market Newswire · 2026/9/24
  • Rating change
    RBC Capital Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $400
    Market Newswire · 2026/10/9
  • RBC Capital Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $375
    Market Newswire · 2026/11/6
  • Rating change
    William Blair Maintains Krystal Biotech(KRYS.US) With Buy Rating
    Market Newswire · 2026/8/4
  • TD Cowen Maintains Krystal Biotech(KRYS.US) With Buy Rating, Cuts Target Price to $380
    Market Newswire · 2026/11/3
  • Rating change
    TD Cowen Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $403
    Market Newswire · 2026/6/18
  • Rating change
    Wolfe Research Maintains Krystal Biotech(KRYS.US) With Hold Rating
    Market Newswire · 2026/8/12
  • Citi Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $412
    Market Newswire · 2026/11/4
  • Rating change
    BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $364
    Market Newswire · 2026/6/1
  • Rating change
    Analysts Have Conflicting Sentiments on These Healthcare Companies: Krystal Biotech (KRYS), AbbVie (ABBV) and Tempus AI, Inc. Class A (TEM)
    TipRanks · 2026/6/1
  • Rating change
    BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Announces Target Price $364
    Market Newswire · 2026/5/22
  • Rating change
    H.C. Wainwright Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $310
    Market Newswire · 2026/6/1
  • Rating change
    TD Cowen Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $403
    Market Newswire · 2026/8/4

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Krystal Biotech discussion 0 comments

Add a comment